nbqx  (Alomone Labs)


Bioz Verified Symbol Alomone Labs is a verified supplier
Bioz Manufacturer Symbol Alomone Labs manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Alomone Labs nbqx
    Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, <t>GYKI-52466</t> and <t>NBQX</t> or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p
    Nbqx, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 11 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nbqx/product/Alomone Labs
    Average 94 stars, based on 11 article reviews
    Price from $9.99 to $1999.99
    nbqx - by Bioz Stars, 2022-08
    94/100 stars

    Images

    1) Product Images from "NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection"

    Article Title: NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

    Journal: Experimental neurology

    doi: 10.1016/j.expneurol.2016.04.010

    Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p
    Figure Legend Snippet: Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Techniques Used: Mouse Assay, Infection

    Weight change in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were weighed daily through day 21 post infection. Data represents percent of daily weight in comparison to weight at day −1, given as mean ± standard error of the mean (SEM) for groups of 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p
    Figure Legend Snippet: Weight change in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were weighed daily through day 21 post infection. Data represents percent of daily weight in comparison to weight at day −1, given as mean ± standard error of the mean (SEM) for groups of 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Techniques Used: Mouse Assay, Infection

    Mortality in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were monitored through day 21 post infection. Data represents percent daily survival in comparison to day 0. The numbers of mice per group at day 0 were 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p
    Figure Legend Snippet: Mortality in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were monitored through day 21 post infection. Data represents percent daily survival in comparison to day 0. The numbers of mice per group at day 0 were 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Techniques Used: Mouse Assay, Infection

    Neuronal cell loss within the hippocampus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. A. Neuronal cell loss was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p
    Figure Legend Snippet: Neuronal cell loss within the hippocampus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. A. Neuronal cell loss was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Techniques Used: Mouse Assay, Infection

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94
    Alomone Labs nbqx
    Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, <t>GYKI-52466</t> and <t>NBQX</t> or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p
    Nbqx, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nbqx/product/Alomone Labs
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    nbqx - by Bioz Stars, 2022-08
    94/100 stars
      Buy from Supplier

    Image Search Results


    Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Journal: Experimental neurology

    Article Title: NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

    doi: 10.1016/j.expneurol.2016.04.010

    Figure Lengend Snippet: Gliosis within the hippocampus and dentate gyrus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. Gliosis was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Article Snippet: TMEV-infected mice were treated, via intraperitoneal (i.p.) injection, with MK 801 (1 mg/kg twice daily, Sigma, St. Louis, MO), GYKI-52466 (10 mg/kg twice daily, Sigma) ( ) or NBQX (approximately 22.5 mg/kg twice daily, Alomone Labs, Jerusalem, Israel) , all in a 25 μl volume, starting on day 2.5 p.i. and stopping on day 10.5 p.i.

    Techniques: Mouse Assay, Infection

    Weight change in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were weighed daily through day 21 post infection. Data represents percent of daily weight in comparison to weight at day −1, given as mean ± standard error of the mean (SEM) for groups of 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Journal: Experimental neurology

    Article Title: NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

    doi: 10.1016/j.expneurol.2016.04.010

    Figure Lengend Snippet: Weight change in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were weighed daily through day 21 post infection. Data represents percent of daily weight in comparison to weight at day −1, given as mean ± standard error of the mean (SEM) for groups of 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Article Snippet: TMEV-infected mice were treated, via intraperitoneal (i.p.) injection, with MK 801 (1 mg/kg twice daily, Sigma, St. Louis, MO), GYKI-52466 (10 mg/kg twice daily, Sigma) ( ) or NBQX (approximately 22.5 mg/kg twice daily, Alomone Labs, Jerusalem, Israel) , all in a 25 μl volume, starting on day 2.5 p.i. and stopping on day 10.5 p.i.

    Techniques: Mouse Assay, Infection

    Mortality in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were monitored through day 21 post infection. Data represents percent daily survival in comparison to day 0. The numbers of mice per group at day 0 were 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Journal: Experimental neurology

    Article Title: NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

    doi: 10.1016/j.expneurol.2016.04.010

    Figure Lengend Snippet: Mortality in antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were monitored through day 21 post infection. Data represents percent daily survival in comparison to day 0. The numbers of mice per group at day 0 were 20 mice (MK 801, GYKI-52466), 19 mice (NBQX) and 60 mice (PBS). †p

    Article Snippet: TMEV-infected mice were treated, via intraperitoneal (i.p.) injection, with MK 801 (1 mg/kg twice daily, Sigma, St. Louis, MO), GYKI-52466 (10 mg/kg twice daily, Sigma) ( ) or NBQX (approximately 22.5 mg/kg twice daily, Alomone Labs, Jerusalem, Israel) , all in a 25 μl volume, starting on day 2.5 p.i. and stopping on day 10.5 p.i.

    Techniques: Mouse Assay, Infection

    Neuronal cell loss within the hippocampus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. A. Neuronal cell loss was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Journal: Experimental neurology

    Article Title: NBQX, a highly selective competitive antagonist of AMPA and KA ionotropic glutamate receptors, increases seizures and mortality following picornavirus infection

    doi: 10.1016/j.expneurol.2016.04.010

    Figure Lengend Snippet: Neuronal cell loss within the hippocampus of antagonist-treated mice. TMEV-infected C57BL/6J mice were treated with MK 801, GYKI-52466 and NBQX or with PBS as a control (treatment: day 2.5–10.5 post infection). Mice were sacrificed on day 21 post infection. A. Neuronal cell loss was scored as described in the Methods. The number of mice in each group is given as N above each column. Data is given as mean + SEM. †p

    Article Snippet: TMEV-infected mice were treated, via intraperitoneal (i.p.) injection, with MK 801 (1 mg/kg twice daily, Sigma, St. Louis, MO), GYKI-52466 (10 mg/kg twice daily, Sigma) ( ) or NBQX (approximately 22.5 mg/kg twice daily, Alomone Labs, Jerusalem, Israel) , all in a 25 μl volume, starting on day 2.5 p.i. and stopping on day 10.5 p.i.

    Techniques: Mouse Assay, Infection